Artificial intelligence and the insights it can provide offer a route for infectious diseases to stay in the spotlight and draw interest from R&D investors worldwide. Liam Tremble at Poolbeg Pharma explores how this technology can be applied to data analysis.
Pharmaceutical R&D is becoming increasingly expensive, and returns on investment (ROIs) have been falling over the last several decades, with static levels of new drug approvals since the 1980s. It is estimated to cost over $2 billion to develop a single product and over 90% of products
which have a filed investigational new drug application (IND) go on to fail. ROI from the pharma sector has fallen from 10% in 2010 to just 2% in 2018 but has recently started to recover.
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.
